Although HER2 is an established therapeutic target in HER2-altered breast cancers, with the development and approval of monoclonal antibodies such as trastuzumab and pertuzumab as well as tyrosine kinase inhibitors (TKIs) such as lapatinib and neratinib [14], it is not the case for lung cancer. This evidence concerns the gene ERBB2 and lung cancer.